Ovid Therapeutics (NASDAQ: OVID) — Perfil da empresa, notícias e dados financeiros
Ovid Therapeutics develops medicines for rare neurological disorders, aiming for transformative therapies.
Ovid Therapeutics
Ovid Therapeutics (NASDAQ:OVID) is a biopharmaceutical company dedicated to developing and commercializing medicines that focus on rare neurological disorders. At the forefront of its operations, the company is involved in several innovative projects aiming to tackle conditions for which the need for effective treatments remains high. Ovid's objectives are centered around creating transformative therapies that can significantly improve patients' lives by targeting the underlying causes of these disorders. Through rigorous research and collaborative efforts, Ovid strives to bring hope and solutions to individuals and families affected by rare neurological conditions, highlighting its commitment to making a meaningful difference in the healthcare landscape.
Resumo
Operações
Produtos e/ou serviços de Ovid Therapeutics
- Soticlestat (TAK-935/OV935), in collaboration with Takeda, focuses on rare epilepsies, targeting cholesterol 24-hydroxylase, a brain-specific enzyme implicated in seizure disorders.
- A precision medicine approach for rare neurological conditions, employing advanced genetic insights to develop targeted therapies.
- Research collaboration with Columbia University to explore genetic drivers of brain disorders, aiming to translate findings into therapeutic candidates.
- Next-generation small molecules for synaptic dysfunction, aiming to address a broad range of CNS disorders by restoring synaptic connectivity.
equipe executiva do Ovid Therapeutics
- Jeremy Max Levin Ba ZoologyCo-Founder & Executive Chairman
- Margaret AlexanderCEO, President & Director
- Jeffrey A. RonaAdvisor
- Charles Ross CarterCFO, Principal Financial Officer, Principal Accounting Officer & Secretary
- Zhong ZhongChief Scientific Officer
- Julia TsaiSenior Vice President of Clinical Development
- Toshiya NishiHead of Epilepsy Research
- Victoria FortChief Strategy Officer
- Petra KaufmannChief Medical Officer
- Kevin NorrettChief Business Officer
Principais indicadores financeiros
Resultados divulgados pela Ovid Therapeutics, em USD.
- Cap. de mercado
- 478,5 mi
- Receita (TTM)
- 1,6 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.2
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 7,3 mi | -42,4 mi | -17,4 mi | |
| 566 mil | -61,9 mi | -26,4 mi | |
| 392 mil | -59,3 mi | -52,3 mi | |
| 1,5 mi | -55,5 mi | -51,4 mi |